Bladder Cancer
1,115
191
273
482
Key Insights
Highlights
Success Rate
82% trial completion
Published Results
168 trials with published results (15%)
Research Maturity
482 completed trials (43% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
9.6%
107 terminated out of 1115 trials
81.8%
-4.8% vs benchmark
10%
109 trials in Phase 3/4
35%
168 of 482 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 482 completed trials
Clinical Trials (1115)
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Evaluation for NCI Surgery Branch Clinical Research Protocols
En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device
KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
DV Plus Toripalimab With Cetirizine and Mecobalamin Pretreatment in Patients With Locally Advanced Unresectable or Metastatic Bladder Cancer
Imaging Study of [89Zr]DFO-YS5 for Cancer Detection
Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Enfortumab Vedotin and Stereotactic Radiation for Localized Bladder Cancer
Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease
A Novel Imaging Protocol in Use to Identify Lymph Nodes and Organs of Interest
Patient-Centered Surgical Prehabilitation
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies
A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer
Guiding Value of Urinary Tumor DNA Testing in Cystoscopy for High-Risk/Very High-Risk Non-Muscle-Invasive Bladder Cancer
DESTINY-PANTUMOUR04
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)